Transition zone defect associated with the response to proton pump inhibitor treatment in patients with globus sensation
Related Experiment Video
Updated: May 14, 2026

Construction of a Wireless-Enabled Endoscopically Implantable Sensor for pH Monitoring with Zero-Bias Schottky Diode-based Receiver
Published on: August 27, 2021
Min Seok Han1, Hyuk Lee, Jung Hyun Jo
1Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Background And Aim:
Few data describing short-term proton pump inhibitor (PPI) treatment in patients with globus sensation exist. The aim of this study was to evaluate the use of high-resolution manometry (HRM) for predicting the response to PPI treatment in patients with globus sensation.
Method:
A total of 41 patients with globus sensation were treated with PPIs for 4 weeks and were classified as positive and negative responders. HRM topographical plots were analyzed for relevant manometric parameters. In addition, clinical and HRM data of 20 patients with typical gastroesophageal reflux disease (GERD) not presenting globus symptom were analyzed.
Results:
Of the 41 patients, 19 (46%) were clinically diagnosed with GERD. The proportion of patients with favorable symptomatic improvement was higher in patients with GERD than in those without reflux (P=0.046). Positive and negative responders to PPI treatment did not differ in upper esophageal sphincter and proximal esophageal contraction. In globus patients with GERD, the temporal and spatial dimension of the transitional zone were greater among negative responders than among PPI-positive responders (P=0.010 and P=0.011). Regarding GERD patients without globus, there was no significant difference in transition zone defect according to PPI responsiveness. By receiver operating characteristic curve analysis, 2.1 cm and 1.1 s were found to be the spatial and temporal transitional zone dimensions that best differentiated positive and negative responders.
Conclusion:
In patients with GERD-related globus, there were larger transition zone defect in the negative responders compared with the PPI-positive responders.
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Peptic Ulcer Disease II: Pathophysiology
